Advik Laboratories Posts Wider Loss of ₹1.02 Crore Amidst Trading Suspension

Advik Laboratories Ltd. has reported a net loss of ₹1.02 crore for the financial year ended March 31, 2026, compared to a loss of ₹0.90 crore in the previous year. The company recorded zero operating revenue for FY26.

Reader Takeaway: Zero revenue and widening losses are concerning, while auditor qualifications and trading suspension highlight significant operational and governance risks.

What just happened

Advik Laboratories announced its audited financial results for FY 2026, revealing a net loss of ₹1.02 crore (₹102.00 lakh). This is an increase from the net loss of ₹0.90 crore (₹89.79 lakh) reported in FY 2025. The company reported no revenue from its operations during FY 2026. Total income for the year stood at ₹0.04 crore, while total expenses amounted to ₹1.09 crore.

Why this matters

The widening net loss coupled with a complete absence of operating revenue signals significant distress for the company. Furthermore, the persistent qualification by the statutory auditor regarding the inability to verify investments worth ₹0.54 crore raises serious governance concerns. The suspension of trading by the BSE due to non-payment of listing fees severely impacts liquidity and investor confidence.

The backstory

Advik Laboratories has been struggling with operational continuity and financial health for some time. The issue of unverified investments due to misplaced share certificates has been a recurring problem since FY 2017-18. Similarly, the company has not paid its annual listing fees to the BSE since FY 2021-22, leading to the current trading restrictions.

What changes now

Trading in Advik Laboratories' shares remains suspended or restricted to 'Trade-for-Trade' settlement on the BSE. For the company, management is actively seeking opportunities to restart business operations and is working on obtaining duplicate share certificates to address the auditor's concerns. Resolution of these issues is critical for potential business revival and resumption of normal trading.

Risks to watch

The primary risks include the company's inability to resolve the auditor's qualification regarding investments, failure to clear outstanding listing fees, and the lack of a clear path to generating operating revenue. Stalled assets also pose a risk if they become obsolete.

Auditor Qualifications and Concerns

The statutory auditor could not verify investments amounting to ₹0.54 crore as the share certificates were reported as misplaced or lost. This qualification has been present since FY 2017-18. Additionally, Capital Work-in-Progress of ₹2.41 crore remains stalled, though management asserts the assets are not obsolete.

Operational and Regulatory Status

Trading in Advik Laboratories scrip is suspended/Trade-for-Trade due to non-payment of Annual Listing Fees to the BSE since FY 2021-22. Management acknowledges the long-standing lack of income from operations and is exploring market opportunities and engaging potential buyers to restart business.

Context metrics (time-bound)

For FY 2026, Advik Laboratories reported operating revenue of ₹0.00 crore, a net loss of ₹1.02 crore, and total income of ₹0.04 crore. Total expenses were ₹1.09 crore. In FY 2025, the net loss was ₹0.90 crore on total income of ₹0.05 crore.